Review ArticleReview

COVID-19 in cancer patients: risk, clinical features, and management

Cuiwei Liu, Yanxia Zhao, Derick Okwan-Duodu, Reva Basho and Xiaojiang Cui
Cancer Biology & Medicine August 2020, 17 (3) 519-527; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0289

Abstract

A novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread across the world, prompting the World Health Organization to declare the coronavirus disease of 2019 (COVID-19) a public health emergency of international concern. Cancer patients are regarded as a highly vulnerable population to SARS-CoV-2 infection and development of more severe COVID-19 symptoms, which is possibly due to the systemic immunosuppressive state caused directly by tumor growth and indirectly by effects of anticancer treatment. Currently, much effort has been directed toward studying the pathogenesis and treatment of COVID-19, but the risk profiles, prognoses, and treatment outcomes in cancer patients remain unclear. Based on the current literature, we summarize the risk profiles, clinical and biochemical characteristics, and therapy outcomes of COVID-19 infections in cancer patients. The challenges in the clinical care of cancer patients with COVID-19 are discussed. The goal of this review is to stimulate research to better understand the biological impact and prognoses of COVID-19 infections in cancer patients, thus facilitating improvement of the clinical management of these patients.

keywords

Introduction

A new coronavirus known as SARS-CoV-2 has spread throughout the world and caused the COVID-19 pandemic1. The symptomatic severity of COVID-19 infection seems to vary with age and the presence of comorbidities2,3. Older patients with chronic underlying diseases, such as cancers, are most vulnerable2,4.

An early study collected and analyzed 2007 COVID-19 cases from 575 hospitals in 31 provincial administrative regions in China1. Among these patients, 18 had a history of cancer, which may reflect a higher incidence of cancer than in the overall Chinese population (0.9% vs. 0.29%)1. This suggests that cancer patients might be more susceptible to SARS-CoV-2 infection. Although the number of COVID-19 cancer patients in this cohort was small, the study reported a higher incidence of acute complications in these patients compared with COVID-19 patients without cancer1,5–7. This finding highlights the need to evaluate clinical outcomes of COVID-19 infection and treatment in cancer patients. This review focuses on the clinical and biological features of COVID-19 infection in cancer patients, to stimulate research into strategies for improving the management of cancer patients with COVID-19.

Risk of SARS-CoV-2 infection in cancer patients

In the COVID-19 pandemic, cancer patients are regarded as a highly vulnerable group due to weakened immune systems caused by both tumor growth and anti-cancer treatment8–11. Furthermore, given the confirmed nosocomial transmission of SARS-CoV-2 among patients in healthcare units2, cancer patients may be more prone to getting infected by SARS-CoV-2 due to contact with COVID-19 patients or virus-contaminated areas, because they need to regularly visit hospitals for anticancer therapy. In a cohort study of 105 cancer patients with COVID-19, Dai et al. reported that lung cancer was the most frequent cancer histology in infected patients (20.95%), followed by gastrointestinal cancer (12.38%), and breast cancer (10.48%)6. Another cohort study of 28 COVID-19 cancer patients reported that patients with Stage IV disease accounted for a higher percentage of infected patients (35.7%), suggesting that later stage cancer patients may be more susceptible to SARS-CoV-25.

In a nationwide cohort study in China, Liang et al. found that the patients with cancer not only had a higher risk of SARS-CoV-2 infection, but also displayed an increased risk of severe clinical events (admission to the intensive care unit, need for invasive ventilation, or death) than those without cancer1. In this study, 39% of cancer patients with COVID-19 developed severe symptoms, compared with only 8% of non-cancer COVID-19 patients1. In a multi-center retrospective study of 105 cancer patients with COVID-19, it was found that patients with hematological malignancies and metastatic solid tumors had a relatively high risk of severe symptoms of 66.67 and 34.29%, respectively6. Another retrospective study reported that the overall fatality among 218 COVID-19 cancer patients from a single medical center in New York City exceeded 25%, which was 2-3-fold greater than their age-adjusted non-cancer counterparts12. Data from the COVID-19 and Cancer Consortium (CCC19) cohort study, which included 1,018 patients, also reported that mortality and severe illness in COVID-19 cancer patients were significantly higher than the general population13.

Notably, a retrospective study of 28 COVID-19 cancer patients found that anti-cancer treatment within 14 days before COVID-19 diagnosis was more frequently associated with severe clinical events due to SARS-CoV-2 infection5. Patients who underwent chemotherapy or surgery in the prior month had a significantly higher risk (75%) of clinically severe events than those who did not receive chemotherapy or surgery (43%)1. Similarly, another study of 205 COVID-19 cancer patients showed that receiving chemotherapy within 4 weeks before symptom onset and male sex were risk factors for death14. Furthermore, a multi-center study reported that COVID-19 cancer patients who received immunotherapy had higher percentages of severe symptoms (66.67%) and death (33.33%). In contrast, patients who received radiotherapy did not show a significant increase in the incidence of severe events6. Of note, thoracic cancer patients who received tyrosine kinase inhibitors had a decreased risk of hospitalization15.

Cancer survivors infected with SARS-CoV-2 also developed increased severity of COVID-19 symptoms compared to COVID-19 patients without a history of cancer1, suggesting that the immune surveillance mechanisms may not have fully recovered in patients with a history of cancer, thus resulting in a weakened defense against COVID-19 disease progression. Apart from disease and treatment-related factors, older age of many cancer patients is an additional risk factor for severe COVID-19 disease1. In addition to severity of the disease, cancer patients developed COVID-19 severe symptoms more rapidly than those without cancer (median time to severe events: 13 days vs. 43 days)1. Furthermore, cancer patients with COVID-19 had more prolonged hospital stays. In a retrospective study, 35.7% of COVID-19 cancer patients were discharged after 13.5 days, while 35.7% remained inpatient after 19 days5. In contrast, a meta-analysis showed that the average discharge rate of non-cancer COVID-19 patients was 52% during a 38-day period16. Together, these data suggest that cancer patients may have an increased risk of COVID-19 and a poorer prognosis.

There are limitations in these cohort studies. They were not prospectively randomized and had a relatively small sample size. Each cohort included diverse cancer types and tumor stages as well as treatment modalities. Furthermore, as treatment strategies for COVID-19 infection continue to improve, older reports may no longer be relevant.

One study indicated that the percentages of SARS-CoV-2 infections, severe events, and deaths in cancer patients undergoing usual SARS-CoV-2 treatment were not higher compared to the general population, due to a low percentage of treatment-related adverse events (5.5%)17. Similarly, breast cancer patients did not appear to have a higher risk of severe COVID-19 than the general population18. Thus, more rigorously designed studies are needed to confirm whether cancer patients develop more severe COVID-19 symptoms upon infection with SARS-CoV-2.

Clinical characteristics of cancer patients with COVID-19

For cancer patients with COVID-19, a retrospective study showed that the most common symptoms at presentation were fever, dry cough, and fatigue5. Although the non-cancer and cancer patients with COVID-19 have similar clinical presentation, fatigue and dyspnea symptoms appear to be more frequent among the latter5,6,19. Especially among COVID-19 patients with lung cancer or lung metastasis, dyspnea was found to occur much earlier from the onset of COVID-19 diagnosis, when compared to both the non-cancer patients and those with other cancer types5,6. This was probably because patients with lung cancer or lung metastasis have a worse baseline lung function and endurance, and thus are more likely to develop severe anoxia and COVID-19 progression.

Besides respiratory symptoms, cancer patients with COVID-19 may also develop a variety of complications1,20–22. The most common complications and cause of deaths in these patients were acute respiratory distress syndrome (ARDS) (28.6%), followed by pulmonary embolism (7.1%), septic shock (3.6%), and acute myocardial infarction (AMI) (3.6%)5. However, another study showed that common complications were liver injury (36.5%), ARDS (17.3%), sepsis (15.4%), myocardial injury (15.4%), renal insufficiency (7.7%), and multiple organ dysfunction syndrome (5.8%) in 52 cancer patients with COVID-1919. Given that cancer patients without COVID-19 also have a high risk of these complications, attributing these symptoms in COVID-19 cancer patients solely to underlying cancer is difficult.

Radiographical and laboratory findings of cancer patients with COVID-19

For both general and cancer patients with COVID-19, the most frequent feature in chest CT imaging was ground-glass opacity, and the second was patchy consolidation5,23. Notably, air bronchogram and interstitial abnormal findings were common in general COVID-19 patients, but not in cancer patients5,23. COVID-19 cancer patients had a higher percentage of bilateral lung involvement than regular patients3,5.

Besides radiographical findings, there are biochemical features associated with COVID-1924,25. One study showed the cytokine release syndrome may be a sign of disease progression26. Higher levels of IL-6 and IL-10 as well as lower levels of CD4+ and CD8+ T cells found in COVID-19 patients correlated with the severity of the disease26. Compared with the general COVID-19 patients, cancer patients with COVID-19 had similar blood counts3,5,19,20. However, there was a higher percentage of COVID-19 cancer patients presenting with anemia4,5. It is possible that anemia in COVID-19 cancer patients is a consequence of nutritional deficiency and an immunosuppressive state, leading to increased susceptibility to respiratory pathogens. A comparison of clinical features in general and cancer COVID-19 patients is shown in Table 1.

View this table:
Table 1

Clinical features in non-cancer and cancer patients with COVID-19

Treatment of COVID-19 in cancer patients

Oxygen therapy for COVID-19 patients

The most important symptomatic treatment for COVID-19 patients is oxygen therapy27. For cancer patients with COVID-19, there was a higher percentage of patients who received oxygen therapy5. The higher proportion of COVID-19 patients with cancer requiring oxygen therapy and mechanical ventilation may be related to more severe disease and an immunosuppressive state in cancer patients, who are more susceptible to secondary lung infection with other pathogens.

Antiviral treatment for COVID-19 patients

Currently, there is no antiviral drug that is specifically effective against SARS-CoV-2. Several clinical studies have indicated that remdsivir, arbidol, and chloroquine may have moderate benefits for treating COVID-1924,28–30. Larger clinical studies need to confirm these results. For cancer patients with COVID-19, the use of antiviral drugs did not yield any different outcomes compared with general COVID-19 patients. About 71.4% of cancer patients with COVID-19 received at least one antiviral agent, including arbidol, lopinavir/ritonavir, ganciclovir, and ribavirin, while 32.1% received two or more antiviral agents5,6.

Immune enhancement therapy for COVID-19 patients

Given that COVID-19 cancer patients may have systemic immunosuppression, intravenous immunoglobulin may be a promising treatment of COVID-19. One study showed that 12 out of 28 cancer patients with COVID-19 received intravenous immunoglobulin treatment. However, the study could not provide adequate information about efficacy due to the limited sample size and lack of a randomized control group5.

Anti-inflammatory therapy for COVID-19 patients

The rationale for anti-inflammatory therapy is based on the premise that COVID-19 induces a cytokine storm with deleterious effects on tissues31. In a controlled, open-label trial, the use of dexamethasone in hospitalized patients with COVID-19 resulted in lower 28-day mortality among those receiving either invasive mechanical ventilation or oxygen alone32. For cancer patients with COVID-19, the use of systemic corticosteroids remains controversial. Given that cancer patients are already at a higher risk of opportunistic infections, the use of corticosteroids may not be effective in mitigating COVID-19 symptoms. Indeed, one study showed that corticosteroids did not reduce the incidence of severe events in cancer patients with COVID-195. Blood purification therapy is an alternative treatment to reduce cytokine storms and benefit critically ill COVID-19 patients. One report showed that the therapy was effective in managing cytokine storms and pathogenic antibodies in three critically ill COVID-19 patients with profound inflammations33. However, larger randomized data were lacking. Furthermore, multi-disciplinary efforts are needed to achieve increased availability of blood purification therapy for COVID-19 cancer patients.

Convalescent plasma therapy for COVID-19 patients

Convalescent plasma therapy has also been explored to alleviate COVID-19 symptoms25,31. Of note, there are some potential risks and ethical issues associated with its usage, including thrombotic risk and the selection of donors. Given that cancer patients with COVID-19 may have a more rapid disease progression, convalescent plasma therapy may be particularly beneficial in this population. To date, there is no report about the effectiveness of convalescent plasma therapy in this patient population. Current reported studies on treatments for general and cancer COVID-19 patients are summarized in Table 2.

View this table:
Table 2

COVID-19 treatments for non-cancer and cancer patients with COVID-19

Therapies for COVID-19 associated with anti-tumor therapies

It is known that immune tolerance is a key part of tumorigenesis and anti-tumor therapy resistance36. Similar to cancer therapy, one method of vaccine development may be a T cell epitope vaccine to enhance the T cell recognition of virus-infected cells. The regimen used to prevent or reduce the cytokine storm in cancer patients during CAR-T cell therapy may also be used to reduce the risk of cytokine storm in COVID-19 patients36. It is known that IL-6 is a critical cytokine involved in cancer and inflammation. High levels of IL-6 predict poor prognoses of patients with COVID-1937. Tocilizumab, an IL-6 receptor-targeted antibody, is approved to alleviate CAR-T cell-induced cytokine release syndrome (CRS) in cancer patients34. Among 129 patients hospitalized for COVID-19, those who received tocilizumab in addition to standard treatment were significantly less likely to need ventilation or die within 2 weeks, when compared with those who received standard treatment alone34. Therefore, antibodies targeting the IL-6 receptor (tocilizumab and sarilumab), IL-6 (siltuximab), and other receptor antagonists (α1-adrenergic receptor antagonist, prazosin) for mitigating cytokine storm are promising therapeutic strategies for the treatment of cancer patients with COVID-1935.

Besides IL-6, other cytokines such as type-I interferon, IL-1β, IL-7, IL-17, and TNF-α are central to the pathophysiology of COVID-1938 as well as to cancer pathogenesis and the therapeutic response39. In particular, IL-17 is a critical cytokine associated with immune responses in both cancer and COVID-19 patients40. Given that anti-IL-17 antibodies have demonstrated a therapeutic role in the treatment of cancer and lung infection by H1N1 and AIDS41, this approach might be useful to control COVID-19 in cancer patients.

The influence of COVID-19 on cancer diagnosis and management

COVID-19 is closely associated with an inflammatory outburst, oxidative stress, and other pathophysiological abnormalities, which can exert tremendous impact on the assessment of cancer and treatment options20,42–44. Notably, a retrospective study showed that there were significant increases in levels of several serum cancer biomarkers in mild cases of COVID-19, when compared to normal control subjects. These cancer biomarkers were further increased in severe cases of COVID-1942. These alterations may affect the positive and negative predictive values of several tumor-related biomarkers, thereby making it challenging to accurately assess and determine cancer diagnosis, disease progression, and therapeutic options.

To reduce the risk of infection in cancer patients, several noncontact diagnostic and screening resources may be used. For example, screening colonoscopy may be delayed or canceled during the pandemic, in preference for DNA-based stool sample tests for colorectal cancer screening45. For cancer patients, more vigorous personal protection and monitoring should be encouraged46,47. Decisions regarding surgical intervention during this time must undergo rigorous ethical and clinical evaluations. Except in emergency cases, it is better to use multidisciplinary conferences to gather consensus regarding surgical therapy because of the higher risk of SARS-CoV-2 infection6,48.

Although patients undergoing chemotherapy seemed to be at a higher risk of severe illness from COVID-196,46, delaying chemotherapy is not recommended, because cancer progression may be exacerbated by COVID-19-elicited inflammatory signals. Therefore, dose reduction of chemotherapy could be considered. Surprisingly, cancer patients undergoing radiotherapy did not show a higher risk of having any severe events from COVID-196, which may be attributed to the activation of the immune system by radiotherapy49. Nevertheless, radiotherapy may need to be safely delivered in a hypofractionated fashion where feasible, to minimize the number of visits to treatment centers50. Regarding targeted therapy, patients who develop fever should undergo COVID-19 testing before continuing treatment51.

Extensive preclinical and clinical data exist on the safety and efficacy of immunotherapy in cancer patients with viral infections52. However, the impact of immune checkpoint inhibitors (ICIs) on COVID-19 pathogenesis and their safety during acute COVID-19 infection is largely unknown. It may be difficult to distinguish features of COVID-19 infection from immune-mediated toxicities related to ICIs53. For example, it is challenging to distinguish anti-PD-1-induced pneumonitis from SARS-CoV-2 infection, because the clinical features are similar. This similarity may also complicate the ensuing management of patients receiving anti-PD-1 therapy with pneumonitis. Furthermore, patients with severe COVID-19 are more likely to have CRS20,53 and overactivated T cells54, which is also a phenomenon of immune hyperactivation typically described in the setting of T cell-engaging immunotherapy including CAR-T cell therapy and ICIs53. CRS and overactivated T cells can cause severe immune-mediated injuries to many organs55 and thus may increase the risk of severe events in cancer patients with COVID-19. Notably, one study showed that prior anti-PD-1 therapy in lung cancer was not associated with an increased risk of severity of COVID-1956. How SARS-CoV-2 virus infection impacts the effectiveness and outcome of anti-cancer therapy largely depends on our ongoing understanding of biochemical and pathophysiological mechanisms of COVID-19.

Conclusions

COVID-19 infection has a tremendous impact on cancer diagnosis, prognosis, and therapeutic effects. Emerging studies show a worse trend among cancer COVID-19 patients compared to non-cancer COVID-19 patients. However, other studies also indicate that the percentages of SARS-CoV-2 infection and severe events in cancer patients are not higher compared to the general population. Therefore, ongoing investigation is needed to better understand the comorbidity of COVID-19 and cancer. The efficacy and safety of COVID-19 treatment approaches in cancer patients also requires further investigation. Because the majority of the reports associated with cancer patients with COVID-19 involve cohort studies with a relatively small sample size, limited clinical information, high heterogeneity of tumor stages and cancer types as well as diverse treatments, current understanding of the comorbidities are limited. Clinical outcomes and the biological basis for the comorbidity of cancer and COVID-19 remain to be resolved. The possibility of COVID-19 recurrence brings a new sense of urgency to develop strategies to optimize the management and care of cancer patients with COVID-19. Although we intend to give a timely summary of the published studies on the impact of COVID-19 on cancer patients, our conclusions could become outdated as studies on the topic are expected to be reported during the ongoing pandemic crisis. We hope to bring attention to the symptoms, prognoses, and treatment options of cancer patients with COVID-19, and to stimulate research into the daunting challenge of addressing COVID-19 and cancer comorbidities.

Acknowledgments

We thank Margarita Castillon for proofreading the manuscript. Xiaojiang Cui is supported by the National Institutes of Health (Grant No. 2R01CA151610), Department of Defense (Grant No. W81XWH-18-1-0067), and a Samuel Oschin Cancer Institute Discovery Fund Award and Community Outreach and Engagement Developmental Fund Award.

Footnotes

  • Conflict of interest statement No potential conflicts of interest are disclosed.

  • Received June 9, 2020.
  • Accepted July 29, 2020.
https://creativecommons.org/licenses/by/4.0/

This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

References

  1. 1.↵
    2. Liang W,
    3. Guan W,
    4. Chen R,
    5. Wang W,
    6. Li J,
    7. Xu K, et al.
    Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21: 335–7.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Wu Z,
    3. McGoogan JM.
    Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020; 323: 1239–42.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Guan W-J,
    3. Ni Z-Y,
    4. Hu Y,
    5. Liang W-H,
    6. Ou C-Q,
    7. He J-X, et al.
    Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med. 2020; 382: 1708–20.
    OpenUrlCrossRefPubMed
  4. 4.↵
    2. Chen N,
    3. Zhou M,
    4. Dong X,
    5. Qu J,
    6. Gong F,
    7. Han Y, et al.
    Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395: 507–13.
    OpenUrlCrossRefPubMed
  5. 5.↵
    2. Zhang L,
    3. Zhu F,
    4. Xie L,
    5. Wang C,
    6. Wang J,
    7. Chen R, et al.
    Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020; 31: 894–901.
    OpenUrlPubMed
  6. 6.↵
    2. Dai M,
    3. Liu D,
    4. Liu M,
    5. Zhou F,
    6. Li G,
    7. Chen Z, et al.
    Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020; 10: 783–91.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    2. Sidaway P.
    COVID-19 and cancer: what we know so far. Nat Rev Clin Oncol. 2020; 17: 336.
    OpenUrlPubMed
  8. 8.↵
    2. Kamboj M,
    3. Sepkowitz KA.
    Nosocomial infections in patients with cancer. Lancet Oncol. 2009; 10: 589–97.
    OpenUrlCrossRefPubMed
  9. 9.
    2. Li J-Y,
    3. Duan X-F,
    4. Wang L-P,
    5. Xu Y-J,
    6. Huang L,
    7. Zhang T-F, et al.
    Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J Immunol Res. 2014; 2014: 286170.
    OpenUrl
  10. 10.
    2. Longbottom ER,
    3. Torrance HDT,
    4. Owen HC,
    5. Fragkou PC,
    6. Hinds CJ,
    7. Pearse RM, et al.
    Features of postoperative immune suppression are reversible with interferon gamma and independent of interleukin-6 pathways. Ann Surg. 2016; 264: 370–7.
    OpenUrlPubMed
  11. 11.↵
    2. Sica A,
    3. Massarotti M.
    Myeloid suppressor cells in cancer and autoimmunity. J Autoimmun. 2017; 85: 117–25.
    OpenUrlPubMed
  12. 12.↵
    2. Mehta V,
    3. Goel S,
    4. Kabarriti R,
    5. Cole D,
    6. Goldfinger M,
    7. Acuna-Villaorduna A, et al.
    Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 2020; 10: 935–41.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    2. Kuderer NM,
    3. Choueiri TK,
    4. Shah DP,
    5. Shyr Y,
    6. Rubinstein SM,
    7. Rivera DR, et al.
    Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020; 395: 1907–18.
    OpenUrlCrossRefPubMed
  14. 14.↵
    2. Yang K,
    3. Sheng Y,
    4. Huang C,
    5. Jin Y,
    6. Xiong N,
    7. Jiang K, et al.
    Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020; 21: 904–13.
    OpenUrlCrossRefPubMed
  15. 15.↵
    2. Garassino MC,
    3. Whisenant JG,
    4. Huang L-C,
    5. Trama A,
    6. Torri V,
    7. Agustoni F, et al.
    COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020; 21: 914–22.
    OpenUrlCrossRefPubMed
  16. 16.↵
    2. Li LQ,
    3. Huang T,
    4. Wang YQ,
    5. Wang ZP,
    6. Liang Y,
    7. Huang TB, et al.
    COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020; 92: 577–83.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Barlesi F,
    3. Foulon S,
    4. Bayle A,
    5. Gachot B,
    6. Pommeret F,
    7. Willekens C, et al.
    Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments. AACR Annual Meeting 2020 Online. April 28, 2020; abstr.CT403.
  18. 18.↵
    2. Vuagnat P,
    3. Frelaut M,
    4. Ramtohul T,
    5. Basse C,
    6. Diakite S,
    7. Noret A, et al.
    COVID-19 in breast cancer patients: a cohort at the institute curie hospitals in the Paris area. Breast Cancer Res. 2020; 22: 55.
    OpenUrl
  19. 19.↵
    2. Yang F,
    3. Shi S,
    4. Zhu J,
    5. Shi J,
    6. Dai K,
    7. Chen X.
    Clinical characteristics and outcomes of cancer patients With COVID-19. J Med Virol. 2020. DOI : 10.1002/jmv.25972.
    OpenUrlCrossRef
  20. 20.↵
    2. Huang C,
    3. Wang Y,
    4. Li X,
    5. Ren L,
    6. Zhao J,
    7. Hu Y, et al.
    Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497–506.
    OpenUrlCrossRefPubMed
  21. 21.
    2. Wang D,
    3. Hu B,
    4. Hu C,
    5. Zhu F,
    6. Liu X,
    7. Zhang J, et al.
    Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323: 1061–9.
    OpenUrlCrossRefPubMed
  22. 22.↵
    2. Xu Z,
    3. Shi L,
    4. Wang Y,
    5. Zhang J,
    6. Huang L,
    7. Zhang C, et al.
    Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8: 420–2.
    OpenUrlPubMed
  23. 23.↵
    2. Shi H,
    3. Han X,
    4. Jiang N,
    5. Cao Y,
    6. Alwalid O,
    7. Gu J, et al.
    Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020; 20: 425–34.
    OpenUrlPubMed
  24. 24.↵
    2. Wang Z,
    3. Yang B,
    4. Li Q,
    5. Wen L,
    6. Zhang R.
    Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020; 71: 769–77.
    OpenUrlPubMed
  25. 25.↵
    2. Wang L-S,
    3. Wang Y-R,
    4. Ye D-W,
    5. Liu Q-Q.
    Review of the 2019 novel coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2020; 55: 105948.
    OpenUrlCrossRefPubMed
  26. 26.↵
    2. Wan S,
    3. Yi Q,
    4. Fan S,
    5. Lv J,
    6. Zhang X,
    7. Guo L, et al.
    Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br J Haematol. 2020; 189: 428–37.
    OpenUrlCrossRef
  27. 27.↵
    2. Yang X,
    3. Yu Y,
    4. Xu J,
    5. Shu H,
    6. Xia J,
    7. Liu H, et al.
    Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8: 475–81.
    OpenUrlPubMed
  28. 28.↵
    2. Wang Y,
    3. Zhang D,
    4. Du G,
    5. Du R,
    6. Zhao J,
    7. Jin Y, et al.
    Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395: 1569–78.
    OpenUrlCrossRefPubMed
  29. 29.
    2. Gao J,
    3. Tian Z,
    4. Yang X.
    Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14: 72–3.
    OpenUrlCrossRefPubMed
  30. 30.↵
    2. Grein J,
    3. Ohmagari N,
    4. Shin D,
    5. Diaz G,
    6. Asperges E,
    7. Castagna A, et al.
    Compassionate use of remdesivir for patients with severe covid-19. N Engl J Med. 2020; 382: 2327–36.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. Tobaiqy M,
    3. Qashqary M,
    4. Al-Dahery S,
    5. Mujallad A,
    6. Hershan AA,
    7. Kamal MA, et al.
    Therapeutic management of patients with COVID-19: a systematic review. Infection Prevention in Practice. 2020; 2: 100061.
    OpenUrlCrossRefPubMed
  32. 32.↵
    2. Horby P,
    3. Lim WS,
    4. Emberson JR,
    5. Mafham M,
    6. Bell JL,
    7. Linsell L, et al.
    Dexamethasone in hospitalized patients with Covid-19 – preliminary report. N Engl J Med. 2020. DOI: 10.1056/NEJMoa2021436.
    OpenUrlCrossRefPubMed
  33. 33.↵
    2. Ma J,
    3. Xia P,
    4. Zhou Y,
    5. Liu Z,
    6. Zhou X,
    7. Wang J, et al.
    Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19. Clin Immunol. 2020; 214: 108408.
    OpenUrlCrossRefPubMed
  34. 34.↵
    2. No authors listed.
    Cytokine storm drugs move from CAR T to COVID-19. Cancer Discov. 2020; 10: OF8.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    2. Konig MF,
    3. Powell M,
    4. Staedtke V,
    5. Bai R-Y,
    6. Thomas DL,
    7. Fischer N, et al.
    Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists. J Clin Invest. 2020; 130: 3345–7.
    OpenUrl
  36. 36.↵
    2. Dong H.
    Seeking and destroying the evils from the inside-translating cancer immunity to fight COVID-19. Cancer Immunol Immunother. 2020; 69: 911–2.
    OpenUrl
  37. 37.↵
    2. Zhao M.
    Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents. 2020; 55: 105982.
    OpenUrlPubMed
  38. 38.↵
    2. Jamilloux Y,
    3. Henry T,
    4. Belot A,
    5. Viel S,
    6. Fauter M,
    7. El Jammal T, et al.
    Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020; 19: 102567.
    OpenUrl
  39. 39.↵
    2. Dranoff G.
    Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004; 4: 11–22.
    OpenUrlCrossRefPubMed
  40. 40.↵
    2. Cafarotti S.
    Severe acute respiratory syndrome-coronavirus-2 infection and patients with lung cancer: the potential role of interleukin-17 target therapy. J Thorac Oncol. 2020; 15: e101-3.
  41. 41.↵
    2. Fabre J,
    3. Giusiniani J,
    4. Garbar C,
    5. Antonicelli F,
    6. Merrouche Y,
    7. Bensussan A, et al.
    Targeting the tumor microenvironment: the protumor effect of IL-17 related to cancer type. Int J Mol Sci. 2016; 17: 1433.
    OpenUrlCrossRef
  42. 42.↵
    2. Wei X,
    3. Su J,
    4. Yang K,
    5. Wei J,
    6. Wan H,
    7. Cao X, et al.
    Elevations of serum cancer biomarkers correlate with severity of COVID-19. J Med Virol. 2020. DOI: 10.1002/jmv.25957.
    OpenUrlCrossRefPubMed
  43. 43.
    2. Davis AP,
    3. Boyer M,
    4. Lee JH,
    5. Kao SC.
    COVID-19: the use of immunotherapy in metastatic lung cancer. Immunotherapy. 2020; 12: 545–8.
    OpenUrlPubMed
  44. 44.↵
    2. Hanna TP,
    3. Evans GA,
    4. Booth CM.
    Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol. 2020; 17: 268–70.
    OpenUrlCrossRefPubMed
  45. 45.↵
    2. Dockter AG,
    3. Angelos GC.
    Molecular-based alternatives for colorectal cancer screening during the COVID-19 pandemic. Surg Technol Int. 2020; 36: 143–7.
    OpenUrl
  46. 46.↵
    2. Burki TK.
    Cancer care in the time of COVID-19. Lancet Oncol. 2020; 21: 628.
    OpenUrl
  47. 47.↵
    2. Spicer J,
    3. Chamberlain C,
    4. Papa S.
    Provision of cancer care during the COVID-19 pandemic. Nat Rev Clin Oncol. 2020; 17: 329–31.
    OpenUrlPubMed
  48. 48.↵
    2. Zacharia BE,
    3. Eichberg DG,
    4. Ivan ME,
    5. Hanft S,
    6. Boockvar JA,
    7. Isildak H, et al.
    Letter: surgical management of brain tumor patients in the COVID-19 era. Neurosurgery. 2020; 87: E197–200.
    OpenUrl
  49. 49.↵
    2. Okwan-Duodu D,
    3. Pollack BP,
    4. Lawson D,
    5. Khan MK.
    Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J Clin Oncol. 2015; 38: 119–25.
    OpenUrlCrossRefPubMed
  50. 50.↵
    2. Nagar H,
    3. Formenti SC.
    Cancer and COVID-19 – potentially deleterious effects of delaying radiotherapy. Nat Rev Clin Oncol. 2020; 17: 332–4.
    OpenUrl
  51. 51.↵
    2. Ascierto PA.
    Experience in using oncology drugs in patients with COVID-19. AACR Annual Meeting 2020 Online. April 28, 2020; abstr.CT405.
  52. 52.↵
    2. Shah NJ,
    3. Al-Shbool G,
    4. Blackburn M,
    5. Cook M,
    6. Belouali A,
    7. Liu SV, et al.
    Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. J Immunother Cancer. 2019; 7: 353.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    2. Bersanelli M.
    Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy. 2020; 12: 269–73.
    OpenUrlPubMed
  54. 54.↵
    2. Liao M,
    3. Liu Y,
    4. Yuan J,
    5. Wen Y,
    6. Xu G,
    7. Zhao J, et al.
    Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020; 26: 842–4.
    OpenUrlPubMed
  55. 55.↵
    2. Zhou F,
    3. Yu T,
    4. Du R,
    5. Fan G,
    6. Liu Y,
    7. Liu Z, et al.
    Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054–62.
    OpenUrlCrossRefPubMed
  56. 56.↵
    2. Luo J,
    3. Rizvi H,
    4. Egger JV,
    5. Preeshagul IR,
    6. Wolchok JD,
    7. Hellmann MD.
    Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers. Cancer Discov. 2020; 10: 1121–8.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords